Biogen's Tau-Targeting Alzheimer's Drug Shows Promise Despite Missing Primary Endpoint
247 Health News Editorial
·15 May 2026
·3 min read
·healthtechBiogen's diranersen reduced tau protein levels in early Alzheimer's patients, with the lowest dose showing optimal cognitive benefits. The Phase 2 trial missed its primary endpoint but revealed promising tau-targeting potential.
Originally reported by STAT News
References
- 1.Feuerstein
- 2.A. (2026
- 3.May 14). Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study. STAT News. https://www.statnews.com/2026/05/14/biogen-alzheimers-tau-diranersen-midstage-study-mixed-results/
- 4.Biogen Inc. (2026). Phase 2 study results of diranersen in early Alzheimer's disease [Press release
2
247 Health News Editorial
247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service